Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 201836 adaptive dose-finding trial in adults with nocturia due to nocturnal polyuria
2016-003851-31Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- May 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of velmupressin in nocturnal polyuria (NP) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Change from baseline in number of nocturnal voids during 12 weeks of treatment. Started May 2017; status: completed.
02
Drugs
velmupressin
03
Conditions
nocturnal polyuria (NP)
Beyond the preview
Go deeper on 2016-003851-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003851-31.